Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study
- PMID: 33757948
- PMCID: PMC7993236
- DOI: 10.1136/bmjopen-2020-044230
Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study
Abstract
Objectives: The aims of our study were to examine the anticholinergic drug use and to assess the association between anticholinergic burden and cognitive function in the multimorbid elderly patients of the MultiCare cohort.
Setting: MultiCare was conducted as a longitudinal cohort study in primary care, located in eight different study centres in Germany.
Participants: 3189 patients (59.3% female).
Primary and secondary outcome measures: Baseline data were used for the following analyses. Drugs were classified according to the well-established anticholinergic drug scale (ADS) and the recently published German anticholinergic burden (German ACB). Cognitive function was measured using a letter digit substitution test (LDST) and a mixed-effect multivariate linear regression was performed to calculate the influence of anticholinergic burden on the cognitive function.
Results: Patients used 1764 anticholinergic drugs according to ADS and 2750 anticholinergics according to the German ACB score (prevalence 38.4% and 53.7%, respectively). The mean ADS score was 0.8 (±1.3), and the mean German ACB score was 1.2 (±1.6) per patient. The most common ADS anticholinergic was furosemide (5.8%) and the most common ACB anticholinergic was metformin (13.7%). The majority of the identified anticholinergics were drugs with low anticholinergic potential: 80.2% (ADS) and 73.4% (ACB), respectively. An increasing ADS and German ACB score was associated with reduced cognitive function according to the LDST (-0.26; p=0.008 and -0.24; p=0.003, respectively).
Conclusion: Multimorbid elderly patients are in a high risk for using anticholinergic drugs according to ADS and German ACB score. We especially need to gain greater awareness for the contribution of drugs with low anticholinergic potential from the cardiovascular system. As anticholinergic drug use is associated with reduced cognitive function in multimorbid elderly patients, the importance of rational prescribing and also deprescribing needs to be further evaluated.
Trial registration number: ISRCTN89818205.
Keywords: clinical pharmacology; epidemiology; primary care.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Comparison of FORTA, PRISCUS and EU(7)-PIM lists on identifying potentially inappropriate medication and its impact on cognitive function in multimorbid elderly German people in primary care: a multicentre observational study.BMJ Open. 2021 Sep 17;11(9):e050344. doi: 10.1136/bmjopen-2021-050344. BMJ Open. 2021. PMID: 34535481 Free PMC article.
-
[The Effect of Patient Age on Anticholinergic Use in the Elderly Japanese Population -Differences between Four Anticholinergic Scales].Yakugaku Zasshi. 2020;140(5):701-710. doi: 10.1248/yakushi.19-00229. Yakugaku Zasshi. 2020. PMID: 32378674 Japanese.
-
Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study.Drugs Aging. 2013 Feb;30(2):103-12. doi: 10.1007/s40266-012-0044-x. Drugs Aging. 2013. PMID: 23239364
-
Anticholinergic Drug Burden and Delirium: A Systematic Review.J Am Med Dir Assoc. 2021 Jan;22(1):65-73.e4. doi: 10.1016/j.jamda.2020.04.019. Epub 2020 Jul 20. J Am Med Dir Assoc. 2021. PMID: 32703688
-
Anticholinergic Burden Measures Predict Older People's Physical Function and Quality of Life: A Systematic Review.J Am Med Dir Assoc. 2021 Jan;22(1):56-64. doi: 10.1016/j.jamda.2020.05.065. Epub 2020 Jul 21. J Am Med Dir Assoc. 2021. PMID: 32709405
Cited by
-
Anticholinergic burden and behavioral and psychological symptoms in older patients with cognitive impairment.Front Med (Lausanne). 2025 Feb 12;12:1505007. doi: 10.3389/fmed.2025.1505007. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40012975 Free PMC article.
-
Anticholinergic medicines - medication management, prescribing cascades, and deprescribing.Int J Clin Pharm. 2025 Aug 13. doi: 10.1007/s11096-025-01965-5. Online ahead of print. Int J Clin Pharm. 2025. PMID: 40802168
-
Development of the Swedish anticholinergic burden scale (Swe-ABS).BMC Geriatr. 2023 Aug 25;23(1):518. doi: 10.1186/s12877-023-04225-1. BMC Geriatr. 2023. PMID: 37626293 Free PMC article.
-
Impact of the Anticholinergic Burden on Disease-Specific Symptoms in Parkinsonian Syndromes.Brain Sci. 2024 Aug 11;14(8):805. doi: 10.3390/brainsci14080805. Brain Sci. 2024. PMID: 39199497 Free PMC article.
-
Disentangling drug contributions: anticholinergic burden in older adults linked to individual medications: a cross-sectional population-based study.BMC Geriatr. 2024 Jan 10;24(1):44. doi: 10.1186/s12877-023-04640-4. BMC Geriatr. 2024. PMID: 38200457 Free PMC article.
References
-
- Ps N, Ms S, Sn H. Anticholinergics: theoretical and clinical overview [online]. Expert Opin Drug Saf 2016. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials